Attached files

file filename
10-K - 10-K - Dimension Therapeutics, Inc.dmtx-10k_20151231.htm
XML - IDEA: XBRL DOCUMENT - Dimension Therapeutics, Inc.R9999.htm
EX-23.1 - EX-23.1 - Dimension Therapeutics, Inc.dmtx-ex231_669.htm
EX-31.1 - EX-31.1 - Dimension Therapeutics, Inc.dmtx-ex311_666.htm
EX-21.1 - EX-21.1 - Dimension Therapeutics, Inc.dmtx-ex211_667.htm
EX-31.2 - EX-31.2 - Dimension Therapeutics, Inc.dmtx-ex312_664.htm
EX-10.15 - EX-10.15 - Dimension Therapeutics, Inc.dmtx-ex1015_668.htm

 

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Dimension Therapeutics, Inc. (the “Company”) for the year ended December 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, that to his knowledge:

 

(1)

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date:  March 24, 2016

By:

/s/ Annalisa Jenkins

 

 

Annalisa Jenkins

 

 

President and Chief Executive Officer

 

 

(Principal Executive Officer)

 

 

 

Date:  March 24, 2016

By:

/s/ Jean Franchi

 

 

Jean Franchi

 

 

Chief Financial Officer

 

 

(Principal Financial Officer)